Immunome Reports the US FDA’s NDA Submission for Varegacestat to Treat Desmoid Tumors in Adults

Shots: The US FDA has received NDA for Immunome’svaregacestat for the treatment of adults with desmoid tumors NDA is supported by the global P-III (RINGSIDE) trial assessing varegacestat (1.2mg, QD) vs PBO until disease progression or death in 156 pts with progressing desmoid tumors; eligible pts could then enter OLE phase, which is ongoing Trial…

ByRidhi RastogiApril 30, 2026

Matthew Robinson, CTO, Immunome Shares Insights on Strategic Collaboration with AbbVie to Identify Multiple Novel Oncology Targets

Shots: Matthew spoke about Immunome’s collaboration and option agreement with AbbVie for the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery Engine He also talked about how the partnership with AbbVie can support Immunome’s strategy to maximize the new drug discovery potential of its Discovery Engine…

BySenior EditorMay 8, 2023

PharmaShots Interview: Purnanand Sarma, CEO of Immunome, Shares Insights on R&D Update IL-38 Targeting Antibody Treatment for Cancer

Shots: Purnanand spoke about the preclinical results of lead candidate in oncology and how its identifies IL-38 as a target to treat cancer Purnanand also talked about Immunome’s collaboration with Fox Chase Cancer Center for the further development of its prime product The interview gives a understanding of Immunome’s goal of developing therapeutics to treat…

BySenior EditorAugust 2, 2022

Immunome Reports the US FDA’s NDA Submission for Varegacestat to Treat Desmoid Tumors in Adults

Matthew Robinson, CTO, Immunome Shares Insights on Strategic Collaboration with AbbVie to Identify Multiple Novel Oncology Targets

PharmaShots Interview: Purnanand Sarma, CEO of Immunome, Shares Insights on R&D Update IL-38 Targeting Antibody Treatment for Cancer

Contact US

FOLLOW US